<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04625881</url>
  </required_header>
  <id_info>
    <org_study_id>Manzana</org_study_id>
    <nct_id>NCT04625881</nct_id>
  </id_info>
  <brief_title>Effects of an Apple Derived Fibre Supplement on Constipation</brief_title>
  <official_title>Effects of an Apple Derived Fibre Supplement on Digestive Symptoms and Evacuation Frequency in People With Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gladys Barrera Acevedo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chile</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will conduct a 2 months clinical intervention in which a 20 g appled derived fibre&#xD;
      supplement will be compared with a placebo without fibre. The main outcome will be the&#xD;
      reduction in the Gastrointestinal System Rating Scale&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants with constipation and mild gastrointestinal symptoms will be invited to&#xD;
      participate. Those with alarming symptoms such as gastrointestinal bleeding or weight loss,&#xD;
      those using laxatives or medications with anticholinergic actions will be excluded from the&#xD;
      study At baseline, participants will be weighed and interrogated about Their gastrointestinal&#xD;
      symptoms using the &quot;Gastrointestinal symptom rating scale&quot; Their type of stools using the&#xD;
      Bristol visual stool scale The number of complete spontaneous bowel movements per week&#xD;
      Afterwards, they will be randomized, balancing by age, gender and body mass index to receive&#xD;
      in a doubly blind fashion A 20 g/day powder with apple derived fiber A similarly looking&#xD;
      placebo powder The intervention will last 8 weeks. Every two weeks, participants will be&#xD;
      cited to provide a new supply of the product, retrieve the used vials and be interrogated&#xD;
      using the same tools as baseline. At the end of the intervention, participants will be&#xD;
      weighed again&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 10, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blind parallel study comparing a fiber supplement with a fiberless placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Active product and placebo will have the same appearance. All vials will have an unique numerical code</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Gastrointestinal symptom rating scale</measure>
    <time_frame>every 2 weeks during 8 weeks</time_frame>
    <description>This scale assesses abdominal pain, bloating and type of stools</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of complete spontaneous bowel movements per week</measure>
    <time_frame>every 2 weeks during 8 weeks</time_frame>
    <description>the title is auto-explicative</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Constipation</condition>
  <condition>Functional Gastrointestinal Disorders</condition>
  <arm_group>
    <arm_group_label>Active product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A powder containing 20 g of apple derived fiber will be consumed daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A rice derived placebo devoid of fiber and aromatized with apple fragancy will be provided</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Apple derived fiber</intervention_name>
    <description>This is a combination of soluble and insoluble fiber</description>
    <arm_group_label>Active product</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  presence of constipation or functional gastrointestinal symptoms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        having serious cardiovascular, kidney or hepatic diseases&#xD;
&#xD;
          -  gastrointestinal bleeding weight loss use of laxatives use of medications with&#xD;
             anticholinergic actions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francisco Perez, Ph D</last_name>
    <phone>+56229781411</phone>
    <email>fperez@inta.uchile.cl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rodrigo Troncoso, PhD</last_name>
    <phone>+56229781486</phone>
    <email>rtroncoso@inta.uchile.cl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Nutrition and Food Technology University of Chile</name>
      <address>
        <city>Santiago</city>
        <state>Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Cornejo, MSc</last_name>
      <phone>+56229781411</phone>
      <email>vcornejo@inta.uchile.cl</email>
    </contact>
    <contact_backup>
      <last_name>Patricio Peirano, MD</last_name>
      <phone>+562291781411</phone>
      <email>ppeirano@inta.uchile.cl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <results_reference>
    <citation>Wiklund IK, Fullerton S, Hawkey CJ, Jones RH, Longstreth GF, Mayer EA, Peacock RA, Wilson IK, Naesdal J. An irritable bowel syndrome-specific symptom questionnaire: development and validation. Scand J Gastroenterol. 2003 Sep;38(9):947-54.</citation>
    <PMID>14531531</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu Z, Yan S, Wu J, He L, Li N, Dong G, Fang J, Fu W, Fu L, Sun J, Wang L, Wang S, Yang J, Zhang H, Zhang J, Zhao J, Zhou W, Zhou Z, Ai Y, Zhou K, Liu J, Xu H, Cai Y, Liu B. Acupuncture for Chronic Severe Functional Constipation: A Randomized Trial. Ann Intern Med. 2016 Dec 6;165(11):761-769. doi: 10.7326/M15-3118. Epub 2016 Sep 13.</citation>
    <PMID>27618593</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 6, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Chile</investigator_affiliation>
    <investigator_full_name>Daniel Bunout</investigator_full_name>
    <investigator_title>Full professor</investigator_title>
  </responsible_party>
  <keyword>constipation</keyword>
  <keyword>dyspepsia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>All information will be in databases without any identification information of participants</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>February 3, 2021</submitted>
    <returned>February 22, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

